Back to search results

Fall Risk and Quality of Life in Cancer Patients with Peripheral Neuropathy

This study is looking at how nerve damage from cancer treatments, called peripheral neuropathy, affects your risk of falling and your overall quality of life. Researchers want to understand if difficulties with thinking, feeling, balance, or movement, including doing two things at once (like walking and texting), contribute to falls or impact your daily life. They are comparing people aged 18 and older who had cancer and now have peripheral neuropathy symptoms, with people of similar age and gender who do not have these symptoms or cognitive issues. The study aims to measure fall risk and quality of life.

Study design
This is an observational study, meaning researchers will observe participants without providing any specific interventions. It plans to enroll 40 individuals.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Fall risk and quality of life will be measured at 5 minutes, which appears to be the duration of the assessment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06313359

Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.

Recruiting
Not specifiedAges 18+Observational
Texas Woman's University
~40 participants
Updated 2025-09-03 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Fall risk
Measured over 5 minutes
+1 more outcome measured

Conditions

Peripheral Neuropathy Due to Chemotherapy

Explore related trials

Malignant NeoplasmPeripheral Neuropathy

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Priya Karakkattil, PhD · PRINCIPAL_INVESTIGATOR · Texas Woman's University
  • Asha Vas, PhD · PRINCIPAL_INVESTIGATOR · Texas Woman's University

Who to contact

Priya Karakkattil
[email protected]
12148625624
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals 18 years and older
diagnosed with non- CNS cancer who underwent treatment and presents with peripheral neuropathy symptoms.
age (+/- one year) and gender matched individuals
no diagnosed peripheral neuropathy
No diagnosed cognitive symptoms.

Exclusion

Unable to follow two step commands.
Unable to ambulate x 50 feet independently without use of an assistive device.
Unable to use a phone to send text messages.
Diagnosis of diabetic peripheral neuropathy
Diagnosis of CNS cancer.
Unable to speak/understand English

What this trial measures

  • Fall risk5 minutes

    Fall risk will be assessed using the Timed Up and Go (TUG)-Test. For the TUG, the participant will be asked to stand up from a chair, walk 3 m and touch a line on the floor, walk back to the chair and sit down. Timing of the test will begin when the tester gives the command "go" and will be stopped when the participant made contact with the chair as they sat down.

  • Quality of life- in cancer patients5 minutes

    Participants in the cancer related peripheral neuropathy group will complete the Functional Assessment of Cancer Therapy- General (FACT-G ) to assess self-reported quality of life. The FACT-G uses a 5-point Likert scale, with higher numbers indicating a better health state.